Welcome to our dedicated page for Biostem Tech news (Ticker: BSEM), a resource for investors and traders seeking the latest updates and insights on Biostem Tech stock.
BioStem Technologies, Inc. (BSEM) delivers innovative regenerative medicine solutions through placental-derived allografts processed via its proprietary BioREtain® method. This page provides timely updates on clinical advancements, regulatory milestones, and operational developments critical to stakeholders in advanced wound care and MedTech.
Access official press releases covering clinical trial outcomes, product innovations, and strategic partnerships. Investors and healthcare professionals will find verified updates on FDA-cleared products, manufacturing expansions, and research collaborations that demonstrate BSEM’s commitment to improving patient outcomes.
All content is curated to meet rigorous compliance standards, with disclosures processed through BSEM’s AATB-accredited facilities. Bookmark this page for direct access to primary-source updates on BioStem’s progress in transforming wound care through biologically active therapies.
BioStem Technologies (OTCQB: BSEM) commends a recent report by the U.S. Department of Health and Human Services Office of Inspector General, highlighting the failure of the Centers for Medicare and Medicaid Services (CMS) to ensure accurate Average Sales Price (ASP) reporting for skin substitute products. The report reveals compliance issues that could affect payment accuracy. CEO Jason Matuszewski emphasizes the importance of accurate ASP reporting for patient access to effective treatments and fair reimbursement for providers. BioStem is committed to regulatory compliance and has implemented measures to ensure transparency in reporting.
BioStem Technologies Inc. (OTCQB: BSEM) announced its acquisition of the majority assets from Auxocell Laboratories, Inc., a leading manufacturer in solid tissue processing equipment. This acquisition includes all assets excluding the AUX003 patent family, which will be licensed to BioStem. The deal encompasses 45 patents and 11 trademarks related to human placental tissue applications. The acquisition aims to enhance BioStem's intellectual property portfolio and manufacturing capabilities while accelerating growth in regenerative medicine. CEO Jason Matuszewski emphasized the strategic value of Auxocell's technology in producing regenerative products without enzymatic digestion.
FAQ
What is the current stock price of Biostem Tech (BSEM)?
What is the market cap of Biostem Tech (BSEM)?
